The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 dose escalation (DE) and cohort expansion (CE) study of ERY974, an anti-Glypican 3 (GPC3)/CD3 bispecific antibody, in patients with advanced solid tumors.
 
Yoshitaka Ogita
Employment - Chugai Pharma; Chugai Pharma USA
 
Daniel Weiss
Employment - Celgene; Chugai Pharma USA
Stock and Other Ownership Interests - Celgene
 
Naofumi Sugaya
Employment - Chugai Pharma (I); Chugai Pharma Europe; Chugai Pharma Europe (I); Churchill Pharmaceuticals
 
Mikiko Nakamura
Employment - Churchill Pharmaceuticals
 
Hajime Ito
Employment - Churchill Pharmaceuticals
 
Takahiro Ishiguro
Employment - Churchill Pharmaceuticals
 
Sumire Shimada
Employment - Churchill Pharmaceuticals
 
Masamichi Ueda
Employment - Churchill Pharmaceuticals
 
Junnosuke Matsushima
Employment - Churchill Pharmaceuticals
 
Athos Gianella-Borradori
Employment - Chugai Pharma
Leadership - Chugai Pharma
Honoraria - Chugai Pharma
Travel, Accommodations, Expenses - Chugai Pharma